As mentioned above, KRAS mutations have been associated with lack of response for EGFR TKIs and due to the paucity of KRAS targeted therapies in the past, KRAS mutant tumor have been hard to treat with targeted therapies. This evidence concerns the gene KRAS and neoplasm.